| AHT | Anti-hormone therapy |
| BCL2i | BCL-2 inhibitors |
| CDK46i | Cyclin-dependent kinase 4/6 inhibitors |
| CDX | Cell-derived mice xenograft |
| CI | Combination index |
| FAKi | Focal adhesion kinase inhibitors |
| GR | Growth rate |
| HGSOC | High-grade serous ovarian cancer |
| IHC | Immunohistochemistry |
| LGSOC | Low-grade serous ovarian cancer |
| MAPK | Mitogen-activated protein kinase |
| MEKi | MEK inhibitors |
| OS | Overall survival |
| PFS | Progression-free survival |
| PLB | Palbociclib |
| Rb | Retinoblastoma |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RR | Response rates |
| SD | Standard deviation |
| SEM | Standard error of the mean |
| TMA | Tissue microarray |
| TRA | Trametinib |
| TRA_R | TRA-resistant |
| TRA_SR | TRA-super resistant |
| WB | Western blot |